Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erhan Keles

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Biomolecular Structure & Dynamics|June 2, 2026
Decoding PI3K isoform selectivity through an ensemble-based framework integrating correlated motions, allosteric networks, and hydration thermodynamicsKevser Kübra Kırboğa, Erhan Keles
Biomaterials Science|August 3, 2016
Recent progress in nanomaterials for gene delivery applicationsErhan Keles, Yang Song, Dan Du, et al.
RSC Medicinal Chemistry|May 27, 2021
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeabilityChiara Borsari, Erhan Keles, Andrea Treyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2017
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in GlioblastomasSung Hugh Choi, Daniel W Stuckey, Sara Pignatta, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine MoietyChiara Borsari, Denise Rageot, Florent Beaufils, et al.
Journal of the American Chemical Society|March 30, 2022
Covalent Proximity Scanning of a Distal Cysteine to Target PI3KαChiara Borsari, Erhan Keles, Jacob A McPhail, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
Chemical Science|November 21, 2024
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signalingLukas Bissegger, Theodora A Constantin, Erhan Keles, et al.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Biomolecular Structure & Dynamics|June 2, 2026
Decoding PI3K isoform selectivity through an ensemble-based framework integrating correlated motions, allosteric networks, and hydration thermodynamicsKevser Kübra Kırboğa, Erhan Keles
Biomaterials Science|August 3, 2016
Recent progress in nanomaterials for gene delivery applicationsErhan Keles, Yang Song, Dan Du, et al.
RSC Medicinal Chemistry|May 27, 2021
Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeabilityChiara Borsari, Erhan Keles, Andrea Treyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2017
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in GlioblastomasSung Hugh Choi, Daniel W Stuckey, Sara Pignatta, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine MoietyChiara Borsari, Denise Rageot, Florent Beaufils, et al.
Journal of the American Chemical Society|March 30, 2022
Covalent Proximity Scanning of a Distal Cysteine to Target PI3KαChiara Borsari, Erhan Keles, Jacob A McPhail, et al.
Journal of Medicinal Chemistry|November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological DisordersChiara Borsari, Erhan Keles, Denise Rageot, et al.
Chemical Science|November 21, 2024
Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signalingLukas Bissegger, Theodora A Constantin, Erhan Keles, et al.
Journal of Medicinal Chemistry|June 28, 2019
(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.
Pageof 1